Organon Korea

Organon Korea is the South Korean subsidiary of Organon, a global healthcare company dedicated to improving the health of women throughout their lives. Formed as a spinoff from MSD in 2021, the company operates with a focus on three core areas: Women's Health, Biosimilars, and Established Brands. Its portfolio includes leading treatments in contraception, fertility, and menopause, as well as a significant presence in the biosimilar market through a strategic partnership with Samsung Bioepis. Additionally, Organon Korea manages a robust collection of established brands in cardiovascular, respiratory, and dermatology therapeutic areas. The company is committed to addressing the unique healthcare needs of the Korean population by providing innovative medicines and fostering local collaborations.